Future of HIPEC for ovarian cancer
- PMID: 36073560
- DOI: 10.1111/1471-0528.17289
Future of HIPEC for ovarian cancer
References
REFERENCES
-
- Vos LMC, Aronson SL, van Driel WJ, Huitema ADR, Schagen van Leeuwen JH, Lok CAR, et al. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:86-102.
-
- van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230-40.
-
- Wu Q, Wu Q, Xu J, Cheng X, Wang X, Lu W, et al. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis. Int J Hyperthermia. 2019;36(1):562-72.
-
- Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019;125(Suppl 24):4594-7.
-
- Koole SN, van Driel WJ, Sonke GS. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. Cancer. 2019;125(Suppl 24):4587-93.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical